Institute for Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom.
Department of Intensive Care Medicine, Royal Liverpool University Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom.
Thromb Haemost. 2020 Dec;120(12):1654-1667. doi: 10.1055/s-0040-1721487. Epub 2020 Dec 23.
COVID-19 was first described in late 2019 and has since developed into a pandemic affecting more than 21 million people worldwide. Of particular relevance for acute care is the occurrence of COVID-19-associated coagulopathy (CAC), which is characterised by hypercoagulability, immunothrombosis and venous thromboembolism, and contributes to hypoxia in a significant proportion of patients. This review describes diagnosis and treatment of CAC in the emergency department and in intensive care. We summarise the pathological mechanisms and common complications of CAC such as pulmonary thrombosis and venous thromboembolic events and discuss current strategies for thromboprophylaxis and therapeutic anti-coagulation in the acute care setting.
COVID-19 于 2019 年末首次被描述，此后已发展成为一种影响全球超过 2100 万人的大流行病。对于急性护理特别相关的是 COVID-19 相关的凝血病 (CAC) 的发生，其特征是高凝状态、免疫血栓形成和静脉血栓栓塞，并且在很大比例的患者中导致缺氧。这篇综述描述了在急诊科和重症监护病房中 CAC 的诊断和治疗。我们总结了 CAC 的病理机制和常见并发症，如肺血栓和静脉血栓栓塞事件，并讨论了急性护理环境中目前的血栓预防和治疗性抗凝策略。
